New Trasylol Label Tightens Kidney Warning, Restricts Usage




WASHINGTON - New safety warnings have been added to the Trasylol label, and the FDA has limited the type of situations where the drug may be used, according to a statement released by the federal agency.

The Dec. 15 release by the FDA noted that Trasylol, often given to patients prior to heart surgery to reduce bleeding, should only be given to patients at an increased risk of blood loss or blood transfusion. Additionally, the FDA has approved changes to the drug's warning label, indicating that those who receive injections of Trasylol face a possible risk of kidney damage.

According …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference: Managing Mass Torts, Status of Key Litigations and Lessons Learned

March 29, 2023 - Tucson, AZ
Hotel Details in Tucson, Arizona, to be Announced

MORE DETAILS



HarrisMartin's New Jersey Asbestos Litigation Conference

March 03, 2023 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS